Intra-Cellular Therapies Operating Income

Intra-Cellular Therapies (ITCI) currently reports a operating income of $-120M as of December 2024. That compares with $-160M in the prior-year period — up 26.8% year over year. Use the charts on this page to explore Intra-Cellular Therapies's operating income history and peer comparisons.

Intra-Cellular Therapies's operating income increased from $-160M to $-120M — a 26.8% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intra-Cellular Therapies reported $-120M in operating income as of December 2024. That compares with $-160M in the prior-year period — up 26.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.

Intra-Cellular Therapies is classified in the Healthcare sector. On operating income, it currently shows $-120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ITCI with unrelated industries.